Home›Screener›GH›Profile
D
41/100

Guardant Health

GHOncology Diagnostics
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Guardant Health (GH) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[1].

GH has 29 Form 4 insider filings recorded at the SEC in the past 30 days[2].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. SEC EDGAR · 0001576280 (2026-04-11) ↗
🔬
Clinical Trials
4
NCT05059444Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05117840Lung Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05935384Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06880055Colo-rectal Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
29 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials5
Sector Peers (Oncology Diagnostics)
ADPTAdaptive Biotechnologies
D
Data Provenance
cik1 verified
clinical trial4 verified
insider buy1 verified
trial count1 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR